10.9 MEAD


Ozurdex is a biodegradable, sustained-release implant previously approved to treat macular edema related to retinal vein occlusion and to treat noninfectious posterior segment uveitis. MEAD comprised two large, multicenter 3-year clinical trials designed to evaluate dexamethasone 0.7 mg and 0.35 mg to support the regulatory filing.

Quiz Module 10.9

1. The MEAD study examined the efficacy of which of the following?

2. Patients treated with the dexamethasone implant achieved statistically significant and clinically meaningful visual improvements over 3 years with how many injections?